Vaccines and therapeutic agents for tularemia

Bibliography

• TARNVIK A: Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. (1989) 11(3):440-451.
   Google Scholar
• DENNIS DT, INGLESBY TV, HENDERSON DA et al.: Tularemia as a biological weapon: medical and public health management. JAMA (2001) 285(21):2763-2773.
   PubMed Web of Science ®Google Scholar
• ELLIS J, OYSTON PC, GREEN M, TITBALL RW: Tularemia. Clin. Microbiol. Rev. (2002) 15(4):631-646.
   PubMed Web of Science ®Google Scholar
• GILL V, CUNHA BA: Tularemia pneumonia. Semin. Respir. Infect. (1997) 12(1):61-67.
   PubMedGoogle Scholar
• OYSTON PC, QUARRY JE: Tularemia vaccine: past, present and future. Antonie Van Leeuwenhoek (2005) 87(4):277-281.
   Google Scholar
• FULOP M, MASTROENI P, GREEN M, TITBALL RW: Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 19(31):4465-4472.
   PubMed Web of Science ®Google Scholar
• CONLAN JW, SHEN H, KUOLEE R, ZHAO X, CHEN W: Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an αβ T cell- and IFN γ-dependent mechanism. Vaccine (2005) 23(19):2477-2485.
   PubMed Web of Science ®Google Scholar
• CHEN W, KUOLEE R, SHEN H, CONLAN JW: Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb. Pathog. (2004) 36(6):311-318.
   Google Scholar
• CONLAN JW, CHEN W, SHEN H, WEBB A, KUOLEE R: Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb. Pathog. (2003) 34(5):239-248.
   PubMedGoogle Scholar
• CHEN W, SHEN H, WEBB A, KUOLEE R, CONLAN JW: Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine (2003) 21(25-26):3690-3700.
   PubMed Web of Science ®Google Scholar
• SJOSTEDT A: Virulence determinants and protective antigens of Francisella tularensis. Curr. Opin. Microbiol. (2003) 6(1):66-71.
   Google Scholar
• LARSSON P, OYSTON PC, CHAIN P et al.: The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat. Genet. (2005) 37(2):153-159.
   PubMed Web of Science ®Google Scholar
• SJOSTEDT A: Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect. (2006) 8(2):561-567.
   Google Scholar
• LAURIANO CM, BARKER JR, YOON SS et al.: MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc. Natl. Acad. Sci. USA (2004) 101(12):4246-4249.
   Google Scholar
• JOHANSSON A, BERGLUND L, SJOSTEDT A, TARNVIK A: Ciprofloxacin for treatment of tularemia. Clin. Infect. Dis. (2001) 33(2):267-268.
   PubMed Web of Science ®Google Scholar
• OYSTON PC, SJOSTEDT A, TITBALL RW: Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. (2004) 2(12):967-978.
   Google Scholar
• PEREZ-CASTRILLON JL, BACHILLER-LUQUE P, MARTIN-LUQUERO M, MENA-MARTIN FJ, HERREROS V: Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis. (2001) 33(4):573-576.
   PubMed Web of Science ®Google Scholar
• CONLAN JW: Vaccines against Francisella tularensis – past, present and future. Expert Rev. Vaccines (2004) 3(3):307-314.
   Google Scholar
• ENDERLIN G, MORALES L, JACOBS RF, CROSS JT: Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. (1994) 19(1):42-47.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, SHER A: IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. Immunol. (1998) 160(11):5428-5435.
   PubMedGoogle Scholar
• CLEMONS KV, BRUMMER E, STEVENS DA: Cytokine treatment of central nervous system infection: efficacy of IL-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. (1994) 38(3):460-464.
   PubMed Web of Science ®Google Scholar
• PAMMIT MA, BUDHAVARAPU VN, RAULIE EK et al.: Intranasal IL-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob. Agents Chemother. (2004) 48(12):4513-4519.
   PubMed Web of Science ®Google Scholar
• DUCKETT NS, OLMOS S, DURRANT DM, METZGER DW: Intranasal IL-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun. (2005) 73(4):2306-2311.
   PubMedGoogle Scholar
• EIGELSBACH HT, DOWNS CM: Prophylactic effectiveness of live and killed tularemia vaccines I. Production of vaccine and evaluation in the white mouse and guinea-pig. J. Immunol. (1961) 87:415-425.
   PubMed Web of Science ®Google Scholar
• SASLAW S, EIGELSBACH HT, WILSON HE, PRIOR JA, CARHART S: Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. (1961) 107:689-701.
   PubMed Web of Science ®Google Scholar
• SASLAW S, EIGELSBACH HT, PRIOR JA, WILSON HE, CARHART S: Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. (1961) 107:702-714.
   PubMed Web of Science ®Google Scholar
• HORNICK RB, EIGELSBACH HT: Aerogenic immunization of man with live Tularemia vaccine. Bacteriol. Rev. (1966) 30(3):532-538.
   Google Scholar
• ISHERWOOD KE, TITBALL RW, DAVIES DH, FELGNER PL, MORROW WJ: Vaccination strategies for Francisella tularensis. Adv. Drug Deliv. Rev. (2005) 57(9):1403-1414.
   Google Scholar
• PECHOUS R, CELLI J, PENOSKE R et al.: Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect. Immun. (2006) 74(8):4452-4461.
   PubMed Web of Science ®Google Scholar
• ROHMER L, BRITTNACHER M, SVENSSON K et al.: Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infect. Immun. (2006) 74(12):6895-6906.
   PubMed Web of Science ®Google Scholar
• TWINE S, BYSTROM M, CHEN W et al.: A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect. Immun. (2005) 73(12):8345-8352.
   PubMed Web of Science ®Google Scholar
• CONLAN JW, SHEN H, WEBB A, PERRY MB: Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine (2002) 20(29-30):3465-3471.
   PubMed Web of Science ®Google Scholar
• HARTLEY MG, GREEN M, CHOULES G et al.: Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infect. Immun. (2004) 72(7):4109-4113.
   PubMedGoogle Scholar
• MOREIN B, SUNDQUIST B, HOGLUND S, DALSGAARD K, OSTERHAUS A: Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature (1984) 308(5958):457-460.
   PubMed Web of Science ®Google Scholar
• GOLOVLIOV I, ERICSSON M, AKERBLOM L et al.: Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine (1995) 13(3):261-267.
   PubMed Web of Science ®Google Scholar
• ELKINS KL, RHINEHART-JONES TR, STIBITZ S, CONOVER JS, KLINMAN DM: Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. (1999) 162(4):2291-2298.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM, CONOVER J, COBAN C: Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. (1999) 67(11):5658-5663.
   PubMed Web of Science ®Google Scholar
• RAJANANTHANAN P, ATTARD GS, SHEIKH NA, MORROW WJ: Novel aggregate structure adjuvants modulate lymphocyte proliferation and TH1 and TH2 cytokine profiles in ovalbumin immunized mice. Vaccine (1999) 18(1-2):140-152.
   PubMedGoogle Scholar
• MORROW WJ, YANG YW, SHEIKH NA: Immunobiology of the Tomatine adjuvant. Vaccine (2004) 22(19):2380-2384.
   PubMed Web of Science ®Google Scholar
• O’HAGAN DT, SINGH M, ULMER JB: Microparticles for the delivery of DNA vaccines. Immunol. Rev. (2004) 199:191-200.
   Google Scholar
• FULOP M, MANCHEE R, TITBALL R: Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol. Med. Microbiol. (1996) 13(3):245-247.
   PubMedGoogle Scholar